Re­searchers out­line an­oth­er big dis­ease tar­get for No­var­tis’ canakinum­ab as drug slash­es rate of gout flares

We’ve al­ready seen No­var­tis’ out­line of pos­i­tive da­ta un­der­scor­ing canakinum­ab’s abil­i­ty to re­duce risks for car­dio pa­tients by tamp­ing down on the in­ter­leukin-1β path­way. Now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.